Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × Azithromycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

COVID-19 2 Skin Neoplasms 1 Respiratory Sounds 1 Respiratory Distress Syndrome 1 Pneumonia, Viral 1 Pharmacokinetics 1 Neoplasms 1 Lymphoma, Follicular 1 Hematologic Neoplasms 1 Cytokine Release Syndrome 1 Asthma 1 Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 78 fludarabine 69 fludarabine phosphate 43 Tacrolimus 41 Whole-Body Irradiation 39 Mycophenolic Acid 36 Busulfan 31 Melphalan 28 Methotrexate 21 Antilymphocyte Serum 21 thymoglobulin 20 Standard of Care 20 Sirolimus 20 Thiotepa 19 Rituximab 19 venetoclax 17 Stem Cell Transplantation 17 Azacitidine 17 Practice Guidelines as Topic 16 Granulocyte Colony-Stimulating Factor 16 Bortezomib 15 Cytarabine 14 Blood Specimen Collection 14 Specimen Handling 13 Filgrastim 13 Surveys and Questionnaires 12 Nivolumab 12 Mesna 12 Peripheral Blood Stem Cell Transplantation 10 Interviews as Topic 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04392128 2020-09-04

HYACINTHE

Institut de cancérologie Strasbourg Europe

Phase 2 Withdrawn

Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡